This two-day workshop is intended to bring together practitioners from the radionuclide metrology, nuclear medicine, and medical physics communities to discuss issues and needs for accurate measurements and standards for alpha-emitting radionuclides being used or investigated for therapeutic nuclear medicine applications. It is organized in collaboration with the EURAMET AlphaMet project. Participation from the radiopharmacies, isotope producers, and radiopharmaceutical manufacturers will also be a critical part of the workshop.
Information gathered from the Workshop will be used as input for a guidance document aimed at improving radioactivity measurement practice for current and anticipated applications in Targeted Alpha Therapy, both in the clinic and in the calibration laboratory. Specific needs and recommendations for the metrology community that are identified during the Workshop will be published separately as a CCRI document.
- Current and future clinical applications in targeted alpha therapy (TAT)
- Measurement needs for the safe and effective implementation of dosimetry-based treatment planning and optimization for TAT
- An update from major manufacturers about products under development
- International metrology infrastructure for radioactivity measurement in nuclear medicine
- Challenges for image-based dosimetry (focus on SPECT and the role of theranostics)
- Radioactivity standards for alpha-emitting radionuclides
- Needs for new and improved decay data
- Specific measurement issues related to alpha emitters (multiple decay progreny, mixed decay modes, non-equilibrium , etc.)
- Radiation protection issues associated with TAT
- Dissemination of standards to end-users